Buy tech sell-off, Wedbush’s Ives says: ’this is a 1996 moment, not 1999’
DUBLIN - Investment firm Citadel Group has disclosed a 1.35% interest in Mural Oncology plc, according to a regulatory filing published Thursday.
The disclosure, made under the Irish Takeover Panel rules, shows Citadel holds 234,108 shares representing 1.35% of the Irish biopharmaceutical company, alongside a short position of 1.17%.
According to the filing, Citadel’s position includes 220,808 shares owned or controlled, representing 1.27% of the company, plus additional exposure through stock-settled derivatives.
The position was reported as of October 8, 2025, with the disclosure detailing several transactions conducted on that date. These included both purchases and sales of common stock at prices ranging from $2.08 to $2.09 per share.
The filing also revealed Citadel’s options positions, including written call options with various strike prices and expiration dates extending into 2027.
Irish takeover rules require public disclosure when an entity acquires an interest of 1% or more in a company that is subject to takeover regulations.
The disclosure was made through a Form 8.3 filing, which is required under Irish Takeover Panel rules for persons with interests in relevant securities representing 1% or more.
Mural Oncology, listed on the Irish stock exchange, develops therapeutics for cancer treatment. The company’s shares were trading at approximately $2.08 on the day of Citadel’s reported transactions.
The information was disclosed in a regulatory news service announcement based on a formal filing with the Irish Takeover Panel.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.